Achaogen

Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrum efficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.

Achaogen (AKAO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Achaogen (AKAO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Nanocap biotech Achaogen Inc (NASDAQ: AKAO) has been pushed to the brink, with the company  announcing  Monday that it has voluntarily filed for Chapter 11 bankruptcy.

Achaogen's Bankruptcy Filing, Proposed Sale: What You Need to Know

Achaogen (AKAO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Achaogen (AKAO) Upgraded to Buy: Here's Why

Investors need to pay close attention to Achaogen (AKAO) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Achaogen (AKAO) Stock?

Achaogen, Inc. (AKAO) CEO Blake Wise on Q4 2018 Results - Earnings Call Transcript

News for Achaogen Stock (AKAO)